Company Reports Q1 Revenue of $3.61B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 hours ago
0mins
Should l Buy BTSG?
Reports Q1 revenue $3.61B, consensus $3.39B. "We are pleased with the Company's first quarter results, which reflect the team's commitment to patients as well as the operating and growth priorities discussed at the Investor Day in March," said CEO Jon Rousseau. "Our focus continues to be anchored in operational and commercial best practices across the organization while leveraging scale to provide quality and effective services to complex patient populations. As we look ahead to the remainder of 2026, we are focused on growing each of our businesses while executing against our goals and reaching more patients who can benefit from these highly impactful and valuable services."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BTSG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BTSG
Wall Street analysts forecast BTSG stock price to fall
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 47.970
Low
40.00
Averages
43.20
High
50.00
Current: 47.970
Low
40.00
Averages
43.20
High
50.00
About BTSG
BrightSpring Health Services, Inc. provides complementary home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and rehabilitation, it provides comprehensive and more integrated care and clinical solutions in all 50 states to customers, clients and patients. Its services are organized and managed through two reportable segments: Pharmacy Solutions and Provider Services. Pharmacy Solutions segment operates long-term institutional pharmacies, hospice pharmacies, specialty oncology pharmacies, and home infusion centers. It provides infused, injectable, and oral medication services in the home and clinic. Provider Services segment provides a variety of services to help manage the whole-person health of its patients in their homes and communities through services such as home health care and hospice care and long-term specialty care.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BRIGHTSPRING HEALTH SERVICES INC - Q1 NET REVENUE INCREASES 25.6% TO $3.614 BILLION
- Revenue Growth: BrightSpring Health Services reported a 25.6% increase in net revenue for Q1, reaching $3,614 million.
- Financial Performance: The significant rise in revenue indicates strong financial performance and growth within the health services sector.
See More
BrightSpring Health Services Reports Strong Q1 Results and Raises 2026 Guidance
- Financial Performance Growth: BrightSpring achieved net revenue of $3.614 billion in Q1 2026, a 25.6% increase year-over-year, indicating strong demand in the complex health services sector, which is expected to further enhance market share.
- Gross Margin Improvement: The company reported a gross profit of $482 million for Q1, up 42.5% from the same period in 2025, demonstrating significant progress in cost control and service efficiency, which will bolster profitability.
- Significant Net Income Increase: BrightSpring's net income reached $74 million in Q1, a substantial rise from $9 million in Q1 2025, reflecting successful strategies in operational efficiency and market positioning.
- 2026 Guidance Raised: The company has raised its full-year 2026 revenue guidance to between $14.725 billion and $15.225 billion, with expected growth rates of 14.1% to 17.9%, showcasing confidence in future market prospects and a strategic intent for continued expansion.
See More
BrightSpring Health Services Q1 Earnings Exceed Expectations
- Strong Earnings Report: BrightSpring Health Services reported Q1 GAAP EPS of $0.67, beating expectations by $0.40, which reflects a significant improvement in profitability and boosts investor confidence.
- Substantial Revenue Growth: The company achieved Q1 revenue of $3.61 billion, a staggering 129,756.1% year-over-year increase, surpassing market expectations by $220 million, indicating robust performance and growth potential in the market.
- Segment Performance: Pharmacy segment revenue is projected between $12.85 billion and $13.3 billion, reflecting a growth rate of 12.3% to 16.2%, while the provider segment is expected to generate revenue between $1.875 billion and $1.925 billion, with a growth rate of 28% to 31.4%, showcasing strong growth across business lines.
- Positive Future Outlook: The company anticipates adjusted EBITDA of $795 million to $825 million in 2026, representing a growth rate of 28.7% to 33.6%, and the acquisition of Amedysis and LHC is expected to contribute approximately $30 million in adjusted EBITDA in 2026, further enhancing profitability and competitive positioning.
See More
BrightSpring Completes Sale of ResCare Community Living to Sevita
- Transaction Background: BrightSpring Health Services has completed the sale of ResCare Community Living, a move that underscores a commitment to continuity of care for individuals with intellectual and developmental disabilities while ensuring workforce stability.
- Strategic Transition Significance: CEO Jon Rousseau stated that the divestiture was aimed at ensuring high-quality, innovative care for clients, marking a strategic shift for both BrightSpring and Sevita as they focus on their respective missions.
- Service Expansion Potential: Sevita CEO Philip Kaufman highlighted that the acquisition will leverage the strengths of both organizations, enhancing programming and expected to benefit more individuals in need of high-quality support, thereby improving overall service quality.
- Industry Impact: BrightSpring serves over 450,000 customers daily and consistently demonstrates industry-leading quality metrics, and this transaction is expected to further solidify its market position in the complex care sector.
See More
Relative Price Strength Picks Amid Market Volatility
- Market Volatility Context: The market experienced fluctuations this week due to rising oil prices amid escalating uncertainty in the Middle East, causing investor concerns about the potential impact of high oil prices on economic growth; however, signs of market resilience are emerging as stocks begin to rebound.
- Allstate Earnings Outlook: Allstate's expected EPS growth rate for the next three to five years is 19%, significantly higher than the industry average of 7.7%, with a 7.5% upward revision in earnings estimates over the past 60 days, indicating strong financial performance potential.
- Five Below Growth Momentum: Five Below's stock surged 200.1% over the past year, with a projected earnings growth rate of 17.5% for fiscal 2027, and a 16.2% increase in earnings estimates over the past 60 days, reflecting robust performance in the retail sector.
- BrightSpring Health Services: BrightSpring's earnings growth estimate for 2026 stands at an impressive 61%, with a market capitalization of $8.4 billion and a 15% upward revision in earnings estimates over the past 60 days, showcasing significant growth potential in the healthcare services sector.
See More
BrightSpring Health Stock Trend Analysis
- Sustained Price Trend: BrightSpring Health Services, Inc. (BTSG) has seen a 9.2% price increase over the past 12 weeks, reflecting continued investor confidence in its potential upside, thereby enhancing its appeal for short-term investors.
- Stable Short-Term Performance: The stock has gained 0.4% over the last four weeks, indicating that its price trend remains stable, which reduces the risk of a trend reversal in the near term and further solidifies investor confidence.
- Strong Fundamental Support: BTSG currently holds a Zacks Rank of #1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, indicating exceptional performance in earnings estimate revisions and EPS surprises, which could drive short-term price increases.
- Optimistic Broker Recommendations: The average broker recommendation for BTSG is #1 (Strong Buy), demonstrating high optimism among analysts regarding the stock's near-term performance, further enhancing its attractiveness for trend investors.
See More
BRIGHTSPRING HEALTH SERVICES INC - Q1 NET REVENUE INCREASES 25.6% TO $3.614 BILLION
- Revenue Growth: BrightSpring Health Services reported a 25.6% increase in net revenue for Q1, reaching $3,614 million.
- Financial Performance: The significant rise in revenue indicates strong financial performance and growth within the health services sector.
See More
BrightSpring Health Services Reports Strong Q1 Results and Raises 2026 Guidance
- Financial Performance Growth: BrightSpring achieved net revenue of $3.614 billion in Q1 2026, a 25.6% increase year-over-year, indicating strong demand in the complex health services sector, which is expected to further enhance market share.
- Gross Margin Improvement: The company reported a gross profit of $482 million for Q1, up 42.5% from the same period in 2025, demonstrating significant progress in cost control and service efficiency, which will bolster profitability.
- Significant Net Income Increase: BrightSpring's net income reached $74 million in Q1, a substantial rise from $9 million in Q1 2025, reflecting successful strategies in operational efficiency and market positioning.
- 2026 Guidance Raised: The company has raised its full-year 2026 revenue guidance to between $14.725 billion and $15.225 billion, with expected growth rates of 14.1% to 17.9%, showcasing confidence in future market prospects and a strategic intent for continued expansion.
See More
BrightSpring Health Services Q1 Earnings Exceed Expectations
- Strong Earnings Report: BrightSpring Health Services reported Q1 GAAP EPS of $0.67, beating expectations by $0.40, which reflects a significant improvement in profitability and boosts investor confidence.
- Substantial Revenue Growth: The company achieved Q1 revenue of $3.61 billion, a staggering 129,756.1% year-over-year increase, surpassing market expectations by $220 million, indicating robust performance and growth potential in the market.
- Segment Performance: Pharmacy segment revenue is projected between $12.85 billion and $13.3 billion, reflecting a growth rate of 12.3% to 16.2%, while the provider segment is expected to generate revenue between $1.875 billion and $1.925 billion, with a growth rate of 28% to 31.4%, showcasing strong growth across business lines.
- Positive Future Outlook: The company anticipates adjusted EBITDA of $795 million to $825 million in 2026, representing a growth rate of 28.7% to 33.6%, and the acquisition of Amedysis and LHC is expected to contribute approximately $30 million in adjusted EBITDA in 2026, further enhancing profitability and competitive positioning.
See More
BrightSpring Completes Sale of ResCare Community Living to Sevita
- Transaction Background: BrightSpring Health Services has completed the sale of ResCare Community Living, a move that underscores a commitment to continuity of care for individuals with intellectual and developmental disabilities while ensuring workforce stability.
- Strategic Transition Significance: CEO Jon Rousseau stated that the divestiture was aimed at ensuring high-quality, innovative care for clients, marking a strategic shift for both BrightSpring and Sevita as they focus on their respective missions.
- Service Expansion Potential: Sevita CEO Philip Kaufman highlighted that the acquisition will leverage the strengths of both organizations, enhancing programming and expected to benefit more individuals in need of high-quality support, thereby improving overall service quality.
- Industry Impact: BrightSpring serves over 450,000 customers daily and consistently demonstrates industry-leading quality metrics, and this transaction is expected to further solidify its market position in the complex care sector.
See More
Relative Price Strength Picks Amid Market Volatility
- Market Volatility Context: The market experienced fluctuations this week due to rising oil prices amid escalating uncertainty in the Middle East, causing investor concerns about the potential impact of high oil prices on economic growth; however, signs of market resilience are emerging as stocks begin to rebound.
- Allstate Earnings Outlook: Allstate's expected EPS growth rate for the next three to five years is 19%, significantly higher than the industry average of 7.7%, with a 7.5% upward revision in earnings estimates over the past 60 days, indicating strong financial performance potential.
- Five Below Growth Momentum: Five Below's stock surged 200.1% over the past year, with a projected earnings growth rate of 17.5% for fiscal 2027, and a 16.2% increase in earnings estimates over the past 60 days, reflecting robust performance in the retail sector.
- BrightSpring Health Services: BrightSpring's earnings growth estimate for 2026 stands at an impressive 61%, with a market capitalization of $8.4 billion and a 15% upward revision in earnings estimates over the past 60 days, showcasing significant growth potential in the healthcare services sector.
See More
BrightSpring Health Stock Trend Analysis
- Sustained Price Trend: BrightSpring Health Services, Inc. (BTSG) has seen a 9.2% price increase over the past 12 weeks, reflecting continued investor confidence in its potential upside, thereby enhancing its appeal for short-term investors.
- Stable Short-Term Performance: The stock has gained 0.4% over the last four weeks, indicating that its price trend remains stable, which reduces the risk of a trend reversal in the near term and further solidifies investor confidence.
- Strong Fundamental Support: BTSG currently holds a Zacks Rank of #1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, indicating exceptional performance in earnings estimate revisions and EPS surprises, which could drive short-term price increases.
- Optimistic Broker Recommendations: The average broker recommendation for BTSG is #1 (Strong Buy), demonstrating high optimism among analysts regarding the stock's near-term performance, further enhancing its attractiveness for trend investors.
See More
